Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
3
50%
Ph early_phase_1
1
17%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Recruiting4
Completed2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 13 (50.0%)
Phase 22 (33.3%)

Trials by Status

completed233%
recruiting467%

Recent Activity

4 active trials
Showing 5 of 6
recruitingphase_1

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

NCT05667506
recruitingphase_2

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT04684147
recruitingearly_phase_1

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

NCT06316791
recruitingphase_2

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT04586478
completedphase_1

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma

NCT04232826
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05667506Phase 1

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

Recruiting
NCT04684147Phase 2

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
NCT06316791Early Phase 1

Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases

Recruiting
NCT04586478Phase 2

Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting
NCT04232826Phase 1

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma

Completed
NCT04230473Phase 1

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6